Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

enteropathy-associated T-cell lymphoma (EATL) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

enteropathy-associated T-cell lymphoma

MONDO:0019473

Also known as:EATLEATL, type IETTL

Find Clinical TrialsTrials

Overview

An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is seen with increased frequency in regions with a high prevalence of celiac disease.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials10 registered · 4 recruiting

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for enteropathy-associated T-cell lymphoma. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for enteropathy-associated T-cell lymphoma, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for enteropathy-associated T-cell lymphoma. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

10 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 2 PHASE2, 6 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07055477](https://clinicaltrials.gov/study/NCT07055477)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:57 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:86880

GARD

Genetic and Rare Diseases Info Center

GARD:9809

Questions for Your Care Team

→Are any of the 10 active clinical trials a good fit for my situation?
→What is the current development status of brentuximab vedotin, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	17	38%
Research summaries	13	29%
Laboratory research	6	13%
Disease patterns and progression	6	13%
Other research	2	4%
Clinical study results	1	2%

Kisho

enteropathy-associated T-cell lymphoma

Overview

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

SMARCB1/INI1-deficient peripheral T-cell lymphoma: two cases expanding the spectrum of an emerging entity and a review of the literature.

Enteropathy-associated T-cell lymphoma: molecular clonal evolution and its clinical consequences.

Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs.

enteropathy-associated T-cell lymphoma

Overview

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

SMARCB1/INI1-deficient peripheral T-cell lymphoma: two cases expanding the spectrum of an emerging entity and a review of the literature.

Enteropathy-associated T-cell lymphoma: molecular clonal evolution and its clinical consequences.

Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs.